삼천당제약의 화려한 기술력과 차가운 시장의 온도 차: 경구용 인슐린의 미래는 어디로 향하는가 > K-wave Trends

Samchundang Pharm recently held a series of corporate presentations for overseas institutional investors in Hong Kong and Singapore, showcasing its unparalleled R&D capabilities. The decision to preemptively disclose core data through a domestic analyst meeting, even after delaying the originally scheduled April timeline, is interpreted as a strategic move to meet global market expectations based on technical confidence. At this event, the company focused on highlighting the scalability of its proprietary drug delivery platform, 'S-PASS,' led by its oral insulin candidate, 'SCD0503.' This is interpreted as a strong determination to target the next-generation obesity and diabetes treatment market, including semaglutide and tirzepatide, going beyond simply converting injectable insulin into an oral medication.

From a technical perspective, the S-PASS platform presented by Samchundang Pharm is emerging as a key alternative for "oralization technology" that global big pharma companies are closely watching. The ability to maintain drug stability in acidic stomach environments while ensuring high absorption rates, combined with a liver-first delivery method that mimics physiological insulin action, provides a strong competitive edge to overcome the limitations of the existing injectable market. Especially with global giants like Novo Nordisk and Eli Lilly staking their futures on the development of oral obesity treatments, Samchundang Pharm's platform technology is highly likely to serve as a key bargaining chip for future technology transfers or licensing agreements. In fact, the company captured investors' attention at the presentation by unveiling an ambitious roadmap to expand its application range beyond peptides to antibody therapeutics.

Regarding commercialization strategy, Samchundang Pharm has already proven tangible results through its "local champion" strategy. The fact that its Eylea biosimilar, sold through partner Apotex in the Canadian market, captured the No. 1 market share at 66% is a case proving that it is a pharmaceutical company with commercialization capabilities, not just technology ownership. This success experience is being utilized as a strong indicator of credibility in discussions regarding global licensing agreements for its new pipeline. The company emphasized that it is securing sustainable growth momentum by solidifying a virtuous cycle of reinvesting stable profits generated from the Eylea biosimilar business into new platform development.

However, separate from these technological advancements, Samchundang Pharm's stock price has been unable to avoid a severe correction phase, coinciding with the recent overall market crash. The stock, which peaked at over 1 million won in March, has now fallen more than 70% from its high, suffering the humiliation of slipping in market cap rankings. This sharp decline is not solely due to the market-wide panic selling sentiment, but also a result of the failure to recover market trust damaged by past management's block deal cancellation mishaps and disclosure controversies. While investors acknowledge the potential of the technology, they remain skeptical about the actual conclusion of contracts and the management's transparent communication methods.

The current situation for Samchundang Pharm is a difficult challenge that requires solving two tasks simultaneously: "perfect validation of technology" and "restoration of market trust." SCD0503, which recently received Phase 1 clinical trial approval from the European Medicines Agency (EMA), is set for a comparative clinical trial targeting Type 1 diabetes patients at Profil in Germany. If the company successfully secures the final Clinical Study Report (CSR) within the year, it is expected to resolve existing uncertainties at once and gain momentum in partnership discussions with global big pharma. Ultimately, the future of Samchundang Pharm depends on how quickly the data they have presented can be converted into tangible results that can heat up the market's cold eyes.